ASH 2022 | The importance of targeting chromosomal abnormalities in AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the significance of chromosomal abnormalities in acute myeloid leukemia (AML). Whilst mutations in signal genes have been the main focus of AML drug development, many patients have chromosomal abnormalities, including TP53 mutation with complex karyotype, that may prevent them from responding to these treatment strategies. More cytogenetic studies are likely to benefit drug discovery for AML patients with chromosomal abnormalities. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
